Business
Easton Pharmaceuticals Announces Key Management Addition With the Appointment of Dr. Daniel Bagi, M.D. to the Board of Directors; Provides Other Updates
Easton Pharmaceuticals Announces Key Management Addition With the Appointment of Dr. Daniel Bagi, M.D. to the Board of Directors; Provides Other Updates.
About this update from Easton Pharmaceuticals Inc
[{"type":"text","content":"\n\n TORONTO, ON, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Easton Pharmaceuticals (OTC:EAPH) announces the appointment of Dr. Daniel Bagi, MD as Director, President of Business Development.  Provides other updates:\n Dr. Daniel Bagi is a senior executive physician with 27 years international experience in the pharmaceutical industry, with an emphasis in worldwide business development and licensing.  Dr. Bagi has expertise in medical affairs and clinical research, specifically oncology and specialty women’s health products and an excellent knowledge of international regulatory standards. Dr. Bagi has supervised over 15 international clinical trials.  He has a strong business orientation with particular strengths in strategic planning, business development, and product evaluation, having secured numerous license deals for Canada, Mexico and Middle Eastern territories between North American Pharmaceutical and Biotech companies and local partners.  Dr. Bagi also has extensive experience presenting to financial institutions, regulatory agencies, and potential pharmaceutical partners. More recently Dr. Bagi was instrumental in securing sub-licensing agreements for Easton and its Latin American joint venture partner, BMV Medica SA de CV with BAYER for the Bacterial Vaginosis diagnostic product VS-Sense for Mexico, which is already available in Canada, Europe and the USA under different brand names. Product launch is expected to commence in the 4th quarter of 2018. Easton Pharmaceuticals is pleased to have such an accomplished professional as Dr. Bagi on board to assist with our future product planning as Dr. Bagi was also instrumental in securing sub-licensing agreements for AmnioSense and Gynofit with Multi-National Gedeon Richter Plc Of Hungary. Both products have received regulatory approval in Mexico and have commenced sales.  Dr. Bagi’s experience in new business development and worldwide licensing for our product line will help Easton navigate the sometimes uncertain waters of the market, and help Easton focus on the design and execution of key offshore licensing and distribution agreements, enriching our pending commercialization efforts. Mr. Bagi takes over for Carla Pepe who has left the company for other opportunities in Canada. Mr. Bagi joins Mr. Luigi Gentile, John Guerra, Evan Karras and Rober...